Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

InnoCare Pharma Collaborates with ArriVent Biopharma

Friday, July 14, 2023

InnoCare Pharma and ArriVent Biopharma have entered into a clinical development collaboration to assess the combination of two investigational drugs, ICP-189 and furmonertinib, for the treatment of advanced non-small cell lung cancer (NSCLC).

Under the agreement, InnoCare and ArriVent will jointly conduct a clinical study to evaluate the efficacy and safety of combining ICP-189 with furmonertinib in patients with advanced NSCLC.

ICP-189 is an oral allosteric inhibitor of SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase), a protein involved in cell signalling pathways. It is developed as a potential treatment for solid tumours, either as a standalone therapy or in combination with other anti-tumour agents. Early studies of ICP-189 have shown promising pharmacokinetics (PK), a long half-life, and favourable safety and tolerability.

This collaboration represents an opportunity for ArriVent to expand its furmonertinib clinical development programme beyond monotherapy and explore the potential benefits of combination therapy in this setting. If the clinical trials are successful and the combination therapy is approved, the combination of furmonertinib with SHP2 inhibitors like ICP-189 will provide an additional treatment option for patients with advanced or metastatic lung cancer.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024